AZD0837 + Aspirin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Persistent or Permanent Non-valvular Atrial Fibrillation
Conditions
Persistent or Permanent Non-valvular Atrial Fibrillation
Trial Timeline
Oct 1, 2007 → Oct 1, 2008
NCT ID
NCT00623779About AZD0837 + Aspirin
AZD0837 + Aspirin is a phase 2 stage product being developed by AstraZeneca for Persistent or Permanent Non-valvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT00623779. Target conditions include Persistent or Permanent Non-valvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00623779 | Phase 2 | Completed |
Competing Products
20 competing products in Persistent or Permanent Non-valvular Atrial Fibrillation